Patents by Inventor Craig W. Crowley

Craig W. Crowley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20220002430
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: April 20, 2021
    Publication date: January 6, 2022
    Applicant: Genentech, Inc.
    Inventors: Camellia W. ADAMS, Andrew C. CHAN, Craig W. CROWLEY, Henry B. LOWMAN, Gerald R. NAKAMURA, Leonard G. PRESTA
  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20190071511
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: February 26, 2018
    Publication date: March 7, 2019
    Applicant: Genentech, Inc.
    Inventors: Camellia W. ADAMS, Andrew C. CHAN, Craig W. CROWLEY, Henry B. LOWMAN, Gerald R. NAKAMURA, Leonard G. PRESTA
  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20170158773
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: July 22, 2016
    Publication date: June 8, 2017
    Inventors: Camellia W. ADAMS, Andrew C. CHAN, Craig W. CROWLEY, Henry B. LOWMAN, Gerald R. NAKAMURA, Leonard G. PRESTA
  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20140154242
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: September 17, 2013
    Publication date: June 5, 2014
    Applicant: Genentech, Inc.
    Inventors: Camellia W. ADAMS, Andrew C. Chan, Craig W. Crowley, Henry B. Lowman, Gerald R. Nakamura, Leonard G. Presta
  • Immunoglobulin variants and uses thereof
    Patent number: 8562992
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Grant
    Filed: October 22, 2008
    Date of Patent: October 22, 2013
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Andrew C. Chan, Craig W. Crowley, Henry B. Lowman, Gerald R. Nakamura, Leonard G. Presta
  • Immunoglobulin variants and uses thereof
    Patent number: 7799900
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: September 21, 2010
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Andrew C. Chan, Craig W. Crowley, Henry B. Lowman, Gerald R. Nakamura, Leonard G. Presta
  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20090155257
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: October 22, 2008
    Publication date: June 18, 2009
    Applicant: GENENTECH, INC.
    Inventors: CAMELLIA W. ADAMS, ANDREW C. CHAN, CRAIG W. CROWLEY, HENRY B. LOWMAN, GERALD R. NAKAMURA, LEONARD G. PRESTA
  • Ras farnesyl transferase inhibitors
    Patent number: 5843941
    Abstract: Benzodiazepine derivatives represented by the structure below are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases foe which inhibition of the ras farnesyl:protein transferase as indicated.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: December 1, 1998
    Assignees: Genentech, Inc., Board of Regents University of Texas
    Inventors: James C. Marsters, Jr., Michael S. Brown, Craig W. Crowley, Joseph L. Goldstein, Guy L. James, Robert S. McDowell, David Oare, Thomas E. Rawson, Mark Reynolds, Todd C. Somers
  • Method for selecting high-expressing host cells
    Patent number: 5561053
    Abstract: A method for selecting recombinant host cells expressing high levels of a desired protein is described. This method utilizes eukaryotic host cells harboring a DNA construct comprising a selectable gene (preferably an amplifiable gene) and a product gene provided 3' to the selectable gene. The selectable gene is positioned within an intron defined by a splice donor site and a splice acceptor site and the selectable gene and product gene are under the transcriptional control of a single transcriptional regulatory region. The splice donor site is generally an efficient splice donor site and thereby regulates expression of the product gene using the transcriptional regulatory region. The transfected cells are cultured so as to express the gene encoding the product in a selective medium comprising an amplifying agent for sufficient time to allow amplification to occur, whereupon either the desired product is recovered or cells having multiple copies of the product gene are identified.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: October 1, 1996
    Assignee: Genentech, Inc.
    Inventor: Craig W. Crowley
  • Ras farnesyl transferase inhibitors
    Patent number: 5532359
    Abstract: Benzodiazepine derivatives are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases for which inhibition of the ras farnesyl:protein transferase is indicated.
    Type: Grant
    Filed: October 25, 1994
    Date of Patent: July 2, 1996
    Assignees: Genentech, Inc., Board of Regents, The University of Texas System
    Inventors: James C. Marsters, Jr., Michael S. Brown, Craig W. Crowley, Joseph L. Goldstein, Guy L. James, Robert S. McDowell, David Oare, Thomas E. Rawson, Mark Reynolds, Todd C. Somers